Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Intellia Therapeutics Inc Market Cap
From what 30 stock analysts predict, the share price for Intellia Therapeutics Inc (NTLA) might increase by 308.89% in the next year. This is based on a 12-month average estimation for NTLA. Price targets go from $14 to $128. The majority of stock analysts believe NTLA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
NTLA is a stock in Healthcare which has been forecasted to be worth $59.77926 as an average. On the higher end, the forecast price is $128 USD by from and on the lower end NTLA is forecasted to be $14 by David Nierengarten from Wedbush.
These are the latest 20 analyst ratings of NTLA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Whitney Ijem Canaccord Genuity | Buy | $90 | Maintains | Nov 19, 2024 |
| David Nierengarten Wedbush | Neutral | $14 | Reiterates | Nov 18, 2024 |
| Geulah Livshits Chardan Capital | Buy | $91 | Maintains | Nov 18, 2024 |
| Yanan Zhu Wells Fargo | Overweight | $70 | Maintains | Nov 18, 2024 |
| Jay Olson Oppenheimer | Outperform | $60 | Maintains | Nov 11, 2024 |
| Gena Wang Barclays | Overweight | $55 | Maintains | Nov 8, 2024 |
| Salveen Richter Goldman Sachs | Neutral | $20 | Maintains | Oct 25, 2024 |
| David Lebowitz Citigroup | Neutral | $19 | Maintains | Oct 25, 2024 |
| Jack Allen Baird | Neutral | $18 | Maintains | Oct 25, 2024 |
| Geulah Livshits Chardan Capital | Buy | $88 | Maintains | Oct 24, 2024 |
| Luca Issi RBC Capital | Outperform | $54 | Reiterates | Sep 19, 2024 |
| Debanjana Chatterjee Jones Trading | Buy | $41 | Initiates | Sep 17, 2024 |
| Dae Gon Ha Stifel | Buy | $64 | Maintains | Sep 11, 2024 |
| Brian Cheng JP Morgan | Overweight | $55 | Maintains | Aug 12, 2024 |
| Luca Issi RBC Capital | Outperform | $54 | Maintains | Aug 9, 2024 |
| Whitney Ijem Canaccord Genuity | Buy | $73 | Maintains | Jun 27, 2024 |
| Joon Lee Truist Securities | Buy | $120 | Maintains | Jun 24, 2024 |
| Rick Bienkowski Cantor Fitzgerald | Overweight | $65 | Reiterates | Jun 24, 2024 |
| Rick Bienkowski Cantor Fitzgerald | Overweight | $65 | Reiterates | Jun 18, 2024 |
| Rick Bienkowski Cantor Fitzgerald | Overweight | $65 | Reiterates | Jun 4, 2024 |
When did it IPO
2016
Staff Count
526
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. John M. Leonard M.D.
Market Cap
$1.50B
In 2023, NTLA generated $36.3M in revenue, which was a decrease of -30.40% from the previous year. This can be seen as a signal that NTLA's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intellia Therapeutics granted an inducement award to a new employee on December 1, 2024, as part of its 2024 Inducement Plan, aimed at enhancing recruitment efforts.
Why It Matters - The inducement grant signals Intellia's growth and commitment to attract talent, potentially enhancing innovation and future product development, which could positively impact stock performance.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - The FDA has granted Intellia a Regenerative Medicine Advanced Therapy designation for its nex-z treatment targeting hereditary transthyretin amyloidosis with polyneuropathy.
Why It Matters - The FDA's designation can accelerate Intellia's drug development, potentially leading to a quicker market entry and increased revenue, positively impacting the company's stock value.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intellia Therapeutics' investigational therapy, nexiguran ziclumeran (NTLA-2001), received FDA RMAT designation for treating hereditary ATTR amyloidosis with polyneuropathy.
Why It Matters - FDA's RMAT designation for Intellia's nexiguran ziclumeran accelerates its path to market, potentially boosting revenues and enhancing investor confidence in the company's pipeline and innovation.
Fri, 22 Nov 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Intellia Therapeutics stock has fallen 33% in one month. Investors may consider this a potential buying opportunity.
Why It Matters - A 33% drop in Intellia Therapeutics stock signals potential volatility and opportunity for value investors. Analyzing the reasons behind the decline is crucial for informed decision-making.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Intellia has launched the Phase 3 HAELO trial for NTLA-2002, a CRISPR therapy for hereditary angioedema, following positive but limited Phase 2 results. Phase 1 data for nex-z showed stabilization in ATTR amyloidosis.
Why It Matters - The initiation of the Phase 3 trial for NTLA-2002 signals potential market expansion for Intellia, while mixed results from other trials highlight competitive pressures and uncertainty in drug efficacy.
Sat, 16 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Intellia Therapeutics (NASDAQ:NTLA) reported positive Phase 1 trial results for nexiguran ziclumeran, a CRISPR-based therapy for ATTR amyloidosis, developed in collaboration with Regeneron.
Why It Matters - Positive clinical data for Intellia's CRISPR-based therapy could enhance its market position and drive stock performance, indicating potential future profitability and innovation in gene editing.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
